Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Some of the most well-known GLP-1 agonists include Ozempic, Wegovy and Trulicity. Zepbound is the newest GLP-1 medication on the block.

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. With a volume of ...

Weight loss jabs could soon be given to tens of thousands of people in the UK. It is planned the new scheme would lower rates of obesity and ease the burden on the NHS - but people are being ...

The company is one of the two global leaders in diabetes with blockbuster products in Trulicity and recently launched Mounjaro (tirzepatide) to serve this large underserved market. To date ...

They’re even proving to have more beneficial effects on health than scientists thought. Drugs like Ozempic, Wegovy, Trulicity, and Mounjaro aren’t just treating diabetes and obesity, studies have ...